Media stories about Sagent Pharmaceuticals (NASDAQ:SGNT) have been trending somewhat positive on Friday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sagent Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news stories about the company an impact score of 41.1872642877865 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
ILLEGAL ACTIVITY NOTICE: “Sagent Pharmaceuticals (SGNT) Receives Daily News Impact Score of 0.06” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3294031/sagent-pharmaceuticals-sgnt-receives-daily-news-impact-score-of-0-06.html.
Sagent Pharmaceuticals Company Profile
Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.
Receive News & Ratings for Sagent Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.